We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

As the stock market crash continues, I’d buy these 2 FTSE 100 stocks in an ISA right now

These two FTSE 100 (INDEXFTSE:UKX) shares could offer long-term growth prospects, in Peter Stephens’ opinion.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100’s 32% crash since the start of the year could continue in the coming weeks. The situation regarding coronavirus is impossible to accurately predict. That may lead to investors demanding even wider margins of safety from large-cap shares.

However, valuations now suggest there could be opportunities for long-term investors. Many FTSE 100 stocks offer wide margins of safety and the potential for improving returns in the coming years.

XXX

As such, now could be the right time to buy these two stocks as part of a diverse ISA portfolio, and hold them for the long run.

AstraZeneca

AstraZeneca’s (LSE: AZN) defensive characteristics have been evident in recent weeks. Its shares are down by 10% in 2020, which is less than a third of the FTSE 100’s decline.

The company is less reliant on the world economy’s performance for its sales. But disruption to global supply chains and weak economic performance may have a negative impact on the pharmaceutical and biopharmaceutical giant’s performance in the near term.

However, AstraZeneca’s recent updates have shown it’s making headway in delivering improving financial performance. For example, its new medicines recorded sales growth of 62% last year. Since they now make up 42% of its total product sales, they’re likely to have a significant impact on its future financial performance.

The stock’s recent decline means that it appears to offer relatively good value for money. It’s forecast to post a rise in its bottom line of 27% next year. Trading on a price-to-earnings (P/E) ratio of 21. And having a defensive business model means that now could be the right time to buy a slice of AstraZeneca and hold those shares for the long run.

RBS

While AstraZeneca offers defensive characteristics, other FTSE 100 stocks, such as RBS (LSE: RBS), have fallen by a much greater amount than the index in recent weeks. The bank’s share price is down by 52% since the start of the year, as investors have reacted to a challenging outlook for the UK economy.

Furthermore, the banking sector may find the task of generating improving returns more difficult in a low interest rate environment. With interest rates at historic lows and monetary policy likely to remain accommodative over the medium term, the financial prospects for the banking industry could prove to be challenging.

However, RBS now trades on a P/E ratio of around 6. This suggests investors have priced in the potential difficulties it may face, and that it now offers a wide margin of safety.

Certainly, it may experience further declines in the short run. But, with its recent results showing an improving operational performance from the bank, now could be a buying opportunity. That’s the case for long-term investors who can accept short-term volatility for high-potential rewards in the coming years.

Peter Stephens owns shares of AstraZeneca and Royal Bank of Scotland Group. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Friends and sisters exploring the outdoors together in Cornwall. They are standing with their arms around each other at the coast.
Investing Articles

£503 buys 14 shares in this FTSE 250 stock that returned 23.9% annually for the last 15 years

This FTSE 250 stock has averaged a huge return for 15 years. At today's price, £503 buys 14 shares. But…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

£1,000 buys 25 shares in this FTSE 100 stock that’s returned 29.2% annually for the last 10 years

This FTSE 100 mining stock has returned close to 30% a year for a decade. At 3,995p, £1,000 buys 25…

Read more »

Female student sitting at the steps and using laptop
Investing Articles

Down 47%, is this growth stock finally worth buying in May?

With a £288m order book and a hidden pipeline of defence and nuclear contracts, is this growth stock now too…

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

2 REITs yielding 7%+ to consider for passive income in 2026

A REIT backed by the NHS and another backed by Tesco and Sainsbury's with both yielding 7%+. Here's why I'm…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

Just 97 shares of this UK dividend stock generate £238 in passive income

A 5.7% yield, £238 in passive income from just 97 shares, and one of the most divisive dividend stocks on…

Read more »

ISA coins
Investing Articles

£10,000 in an ISA generates a second income of…

The London Stock Exchange is home to some of the world's most generous dividends. But how big a second income…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Expert recommendations: 2 top income stocks yielding 7%+!

With yields of 7.2% and 7.8% respectively, these two income stocks are catching the eyes of institutional analysts. Should investors…

Read more »

Illustration of flames over a black background
Investing Articles

3 top income-focused stocks to buy in May 2026, according to experts

Looking for a stock to buy for income in May 2026? Experts have flagged these three UK dividend shares as…

Read more »